[Discovery of a new gene frequently inactivated in human cancers: protein p16, a cell cycle regulator]
Related Experiment Videos
1Service d'immunologie moléculaire, institut Gustave-Roussy, Villejuif, France.
Abstract:
Comprehension of cell cycle regulation mechanisms progressed very quickly the past few years. The last discovery concern a known gene, MTS1 (Multiple Tumor suppressor), encoding a protein of M(r) 16K, intrinsic component of the cell cycle machinery. p16 protein inhibits an enzyme called CDK4 (cyclin-dependent kinase 4) which is a kinase implicated in the control of cell proliferation between the G1 and S phases. Now, a team reported that MTS1 gene is frequently inactivated in a wide variety of human cancers. This important finding will provide a new link between cell cycle control and oncogenesis, if MTS1 is proved to be a classic tumor suppressor gene.
Insights
The MTS1 gene, encoding the p16 protein, is crucial for cell cycle regulation by inhibiting CDK4. This gene is frequently inactivated in human cancers, suggesting a link between cell cycle control and oncogenesis.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Context:
- Recent advancements in understanding cell cycle regulation.
- Identification of the MTS1 gene and its p16 protein product.
- p16 protein's role in inhibiting cyclin-dependent kinase 4 (CDK4), a key regulator of cell proliferation between G1 and S phases.
Purpose:
- To investigate the role of the MTS1 gene in human cancers.
- To explore the link between cell cycle control and oncogenesis.
Summary:
- The MTS1 gene, which encodes the 16K protein (p16), is a critical component of the cell cycle machinery.
- p16 protein functions by inhibiting CDK4, a kinase essential for controlling cell proliferation.
- A recent study reports frequent inactivation of the MTS1 gene across diverse human cancers.
Impact:
- This discovery establishes a significant connection between cell cycle dysregulation and cancer development.
- MTS1 may function as a classic tumor suppressor gene, offering new avenues for cancer research and therapeutic strategies.